Menotropin (hMG) and idiopathic oligoastenoteratozoospermia (OAT) : effects on seminal fluid parameters and on results in ICSI cycles
Beretta, G.; Fino, E.; Sibilio, L.; Dilena, M.
Archivio Italiano di Urologia Andrologia Organo Ufficiale di Societa Italiana di Ecografia Urologica e Nefrologica 77(1): 18-21
2005
ISSN/ISBN: 1124-3562 PMID: 15906784 Document Number: 593077
Many studies on gonadotropin treatment in idiopathic OAT have produced inconsistent (75 IU FSH + 75 IU LH) at the dosage of 3 ampoules a week for 90 days in 18 patients with idopathic OAT and testicular volume 12-15 ml. At the end of the cycle seminal fluid parameters and testicular volume were reassessed, comparing them with a homogenous control group including 13 subjects awaiting ICSI, who were not given any kind of pharmacological treatment. Treatment produced a statistically significant improvement in spermatozoa concentration (p = 0.016) and reduction in atypical forms (p = 0.040). We assessed also the impact on oocyte fertilization and pregnancy rates after the use of assisted reproduction techniques in a more restricted group of 8 patients, who had already undergone ICSI cycles before pharmacological therapy. Treatment with menotropin (hMG) appears to improve embryo quality.